What are the results of the COMPARE, VENTURE-AF, RE-CIRCUIT, BRUISE-CONTROL and BRUISE-CONTROL Bridge or Continue Coumadin for Device Surgery Randomized Controlled Trials?
The results of the COMPARE trial showed a significant reduction in stroke, TIA, and minor bleeding with uninterrupted warfarin, while the VENTURE-AF trial showed no difference in overall low incidence of major bleeding or thromboembolic events between uninterrupted rivaroxaban and uninterrupted VKA. The RE-CIRCUIT trial showed a significant reduction in major bleeding events with dabigatran compared to warfarin, while the BRUISE-CONTROL trial showed a significant reduction in pocket hematoma with interrupted warfarin and heparin bridging compared to uninterrupted warfarin. Lastly, the BRUISE-CONTROL Bridge or Continue Coumadin for Device Surgery Randomized Controlled Trial showed a significant reduction in pocket hematoma with interrupted warfarin and heparin bridging compared to uninterrupted warfarin.